Is Capricor Therapeutics Stock a Good Investment?
Capricor Therapeutics Investment Advice | CAPR |
- Examine Capricor Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Capricor Therapeutics' leadership team and their track record. Good management can help Capricor Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Capricor Therapeutics' business and its evolving consumer preferences.
- Compare Capricor Therapeutics' performance and market position to its competitors. Analyze how Capricor Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Capricor Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Capricor Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Capricor Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Capricor Therapeutics is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Solid | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Capricor Therapeutics Stock
Researching Capricor Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 17.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.03. Capricor Therapeutics last dividend was issued on the 5th of June 2019. The entity had 1:10 split on the 5th of June 2019.
To determine if Capricor Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Capricor Therapeutics' research are outlined below:
| Capricor Therapeutics is way too risky over 90 days horizon | |
| Capricor Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 25.18 M. Net Loss for the year was (22.29 M) with profit before overhead, payroll, taxes, and interest of 1.75 M. | |
| Capricor Therapeutics currently holds about 51.42 M in cash with (25.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.11. | |
| Capricor Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Roughly 17.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Capricor Therapeutics Stock Surges Amid Positive Analyst Ratings |
Capricor Therapeutics Quarterly Cash And Short Term Investments |
|
Capricor Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Capricor Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Capricor Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Capricor Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Capricor Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-11-12 | 2020-09-30 | -0.18 | -0.2 | -0.02 | 11 | ||
2022-11-10 | 2022-09-30 | -0.29 | -0.26 | 0.03 | 10 | ||
2023-11-14 | 2023-09-30 | -0.29 | -0.25 | 0.04 | 13 | ||
2022-08-10 | 2022-06-30 | -0.25 | -0.29 | -0.04 | 16 | ||
2021-11-09 | 2021-09-30 | -0.22 | -0.17 | 0.05 | 22 | ||
2023-08-07 | 2023-06-30 | -0.35 | -0.29 | 0.06 | 17 | ||
2024-02-29 | 2023-12-31 | -0.09 | -0.02 | 0.07 | 77 | ||
2022-03-10 | 2021-12-31 | -0.19 | -0.26 | -0.07 | 36 |
Know Capricor Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Capricor Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Capricor Therapeutics backward and forwards among themselves. Capricor Therapeutics' institutional investor refers to the entity that pools money to purchase Capricor Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 158.4 K | Partner Fund Management Lp | 2024-09-30 | 152.8 K | Ghost Tree Capital, Llc | 2024-09-30 | 125 K | Stempoint Capital Lp | 2024-09-30 | 93.6 K | Schonfeld Strategic Advisors Llc | 2024-09-30 | 90.4 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 89.3 K | Boothbay Fund Management, Llc | 2024-09-30 | 87.8 K | Ubs O'connor Llc | 2024-09-30 | 82.9 K | Goldman Sachs Group Inc | 2024-06-30 | 82.7 K | Blackrock Inc | 2024-06-30 | 1.6 M | Vanguard Group Inc | 2024-09-30 | 1.6 M |
Capricor Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 855.74 M.Market Cap |
|
Capricor Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.88) | (0.83) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.99) | (0.94) |
Determining Capricor Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Capricor Therapeutics is a good buy. For example, gross profit margin measures Capricor Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Capricor Therapeutics' profitability and make more informed investment decisions.
Evaluate Capricor Therapeutics' management efficiency
Capricor Therapeutics has return on total asset (ROA) of (0.4449) % which means that it has lost $0.4449 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.9269) %, meaning that it created substantial loss on money invested by shareholders. Capricor Therapeutics' management efficiency ratios could be used to measure how well Capricor Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/26/2024, Return On Tangible Assets is likely to drop to -0.4. In addition to that, Return On Capital Employed is likely to grow to -0.83. At this time, Capricor Therapeutics' Total Assets are relatively stable compared to the past year. As of 11/26/2024, Non Current Assets Total is likely to grow to about 8.3 M, while Other Current Assets are likely to drop slightly above 572 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.84 | 0.80 | |
| Tangible Book Value Per Share | 0.84 | 0.80 | |
| Enterprise Value Over EBITDA | (5.15) | (5.41) | |
| Price Book Value Ratio | 5.79 | 6.08 | |
| Enterprise Value Multiple | (5.15) | (5.41) | |
| Price Fair Value | 5.79 | 6.08 | |
| Enterprise Value | 118.5 M | 124.4 M |
Effective leadership at Capricor Therapeutics drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta 4.016 |
Basic technical analysis of Capricor Stock
As of the 26th of November, Capricor Therapeutics shows the Mean Deviation of 6.8, downside deviation of 5.13, and Risk Adjusted Performance of 0.1922. Capricor Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Capricor Therapeutics coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Capricor Therapeutics is priced correctly, providing market reflects its regular price of 19.06 per share. Given that Capricor Therapeutics has jensen alpha of 2.66, we suggest you to validate Capricor Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.Capricor Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Capricor Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Capricor Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Capricor Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Capricor Therapeutics' Outstanding Corporate Bonds
Capricor Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Capricor Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Capricor bonds can be classified according to their maturity, which is the date when Capricor Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Capricor Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Capricor Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1922 | |||
| Market Risk Adjusted Performance | 16.71 | |||
| Mean Deviation | 6.8 | |||
| Semi Deviation | 4.1 | |||
| Downside Deviation | 5.13 | |||
| Coefficient Of Variation | 417.88 | |||
| Standard Deviation | 11.22 | |||
| Variance | 125.93 | |||
| Information Ratio | 0.2278 | |||
| Jensen Alpha | 2.66 | |||
| Total Risk Alpha | 0.9336 | |||
| Sortino Ratio | 0.498 | |||
| Treynor Ratio | 16.7 | |||
| Maximum Drawdown | 69.31 | |||
| Value At Risk | (7.37) | |||
| Potential Upside | 18.22 | |||
| Downside Variance | 26.36 | |||
| Semi Variance | 16.81 | |||
| Expected Short fall | (9.27) | |||
| Skewness | 2.86 | |||
| Kurtosis | 10.85 |
| Risk Adjusted Performance | 0.1922 | |||
| Market Risk Adjusted Performance | 16.71 | |||
| Mean Deviation | 6.8 | |||
| Semi Deviation | 4.1 | |||
| Downside Deviation | 5.13 | |||
| Coefficient Of Variation | 417.88 | |||
| Standard Deviation | 11.22 | |||
| Variance | 125.93 | |||
| Information Ratio | 0.2278 | |||
| Jensen Alpha | 2.66 | |||
| Total Risk Alpha | 0.9336 | |||
| Sortino Ratio | 0.498 | |||
| Treynor Ratio | 16.7 | |||
| Maximum Drawdown | 69.31 | |||
| Value At Risk | (7.37) | |||
| Potential Upside | 18.22 | |||
| Downside Variance | 26.36 | |||
| Semi Variance | 16.81 | |||
| Expected Short fall | (9.27) | |||
| Skewness | 2.86 | |||
| Kurtosis | 10.85 |
Consider Capricor Therapeutics' intraday indicators
Capricor Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Capricor Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 99580.4 | |||
| Daily Balance Of Power | 0.1455 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 19.38 | |||
| Day Typical Price | 19.28 | |||
| Price Action Indicator | (0.21) | |||
| Period Momentum Indicator | 0.24 |
Capricor Therapeutics Corporate Filings
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Capricor Stock media impact
Far too much social signal, news, headlines, and media speculation about Capricor Therapeutics that are available to investors today. That information is available publicly through Capricor media outlets and privately through word of mouth or via Capricor internal channels. However, regardless of the origin, that massive amount of Capricor data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Capricor Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Capricor Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Capricor Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Capricor Therapeutics alpha.
Capricor Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Capricor Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Capricor Therapeutics Corporate Management
| Deborah Ascheim | Chief Medical Officer | Profile | |
| Kristi Elliott | Chief Officer | Profile | |
| Xavier Avat | Chief Officer | Profile | |
| MD FACC | Executive Board | Profile | |
| Catherine Kelleher | Consultant | Profile | |
| Eduardo Marbn | CoFounder Board | Profile |
Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.